http://cdr-life.com/  

8810 Horgen, Tödistrasse 46

 info@cdr-life.com

CDR-Life is a Zurich-based biotech company that discovers and develops innovative medicines for the treatment of high need diseases. We invent and develop therapeutic antibody fragments with a focus on immuno-oncology and ophthalmology.

http://www.cellerys.com/  

8952 Schlieren, Wagistrasse 21

Cellerys is a spin-off from University Hospital and University of Zurich. The company develops new therapies against Multiple Sclerosis (MS).

https://centenara.com/  

8952 Schlieren, Wagistrasse 18

 +41 44 730 12 90
 info@centenara.com

Centenara Labs develops and invests in therapies that target geriatric diseases. Our goal is to expand healthspan, promoting overall health, well-being and longevity as the population ages. Centenara Labs supports pioneers in the field of aging to transform their scientific discoveries into medicines. We are building a product pipeline comprised of potential breakthrough therapeutics that treat diseases of aging and help reduce the growing strain on global healthcare systems as the world’s population ages.

https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor  

8952 Schlieren, Wagistrasse 25

 +41 58 851 80 00

Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.

http://cutiss.swiss  

8952 Schlieren, Grabenstrasse 11

 +41 44 244 36 60
 info@cutiss.swiss

After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.